The variables analyzed were age, number of daily drugs, Charlson comorbidity index, polypharmacy, previous chemotherapy administration, cancer stage, percentage of staining of progesterone and estrogen receptors, Ki67 in breast tissue, presence or not of depression and insomnia at baseline (before receiving AROi treatment). Here, MKI67 is linked to depressive symptom measurement.